World Vaccine Congress Washington: Antibody persistence of a single-dose live-attenuated chikungunya virus vaccine in adults -April 04, 2024 at 01:54 am EDT

Antibody persistence of a single-doselive-attenuated chikungunya virus vaccine in adults.


World Vaccine Congress, Washington 03-Apr-2024


...

Related Keywords

Washington ,District Of Columbia ,United States ,Japan ,Canada ,South Africa ,Paraguay ,Antarctica ,Tanzania ,Brazil ,Philippines ,Japanese ,America ,South African ,Susanne Eder Lingelbach ,Instituto Butantan ,Indianj Dermatol ,Vp Clinical Development ,A Major Public Health Threat ,World Vaccine Congress ,Centers For Disease ,Pfizer ,Health Canada ,Development Status ,Vaccine Congress ,Integrated Expertise ,Lead Phase ,Japanese Encephalitis ,Central America ,Prescribing Information ,Medication Guide ,Enterotoxigenic Escherichia ,Major Public Health Threat ,Latin America ,Tropical Diseases ,Acute Morbidity ,Can Lead ,Chronic Incapacitation ,Disease Control ,Chikungunya Negatively Impacts Quality ,Global Threat ,Virus Disease ,East Central South African ,Preparing Phase ,Primary Endpoint ,Lotconsistency Trial ,Chikungunya Vaccines ,Serological Endpoint ,